Laura Clarke, Simon Arnett, Wajih Bukhari, Elham Khalilidehkordi, Sofia Jimenez Sanchez, Cullen O’Gorman, Jing Sun, Kerri M Prain, Mark Woodhall, Roger Silvestrini, Christine S Bundell,…
Variable results after rituximab in neuromyelitis optica. Lindsey JW, Meulmester KM, Brod SA, Nelson F, Wolinsky JS. Abstract Our objective was to assess the efficacy of rituximab (RTX) in neuromyelitis optica (NMO)
Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica Ingo Kleiter, MD; Kerstin Hellwig, MD; Achim Berthele, MD; Tania K?mpfel, MD; Ralf A. Linker, MD; Hans-Peter Hartung, MD; Friedemann Paul, MD; Orhan Aktas, MD; for the Neuromyelitis Optica Study Group Arch Neurol. ?2012;69(2):239-245.
Case Reports in Medicine Volume 2011 (2011), Article ID 393568, 4 pages doi:10.1155/2011/393568 Case Report Neuromyelitis Optica Spectrum Disease with Positive Autoimmune Indices: A Case Report and Review of the Literature M.
Multiple sclerosis: clinical aspects Sunday, May 29, 2011, 12:00 – 13:00 Neuromyelitis optica spectrum disorder: the importance of NMO-IgG in clinical practice M. Radaelli, V
Hypothermia, Hypotension, Hypersomnia, and Obesity Associated With Hypothalamic Lesions in a Patient Positive for the Anti-aquaporin 4 Antibody: A Case Report and Literature Review. Suzuki K, Nakamura T, Hashimoto K, Miyamoto M, Komagamine T, Nagashima T, Izawa N, Kanbayashi T, Takahashi T, Hirata K. Abstract OBJECTIVE To describe a patient positive for the anti-aquaporin 4 antibody with hypothalamic lesions showing hypothermia, hypotension, hypersomnia, and obesity.
Background: Longitudinally extensive transverse myelitis (LETM) is defined clinically by acute transverse myelitis (ATM) and radiologically by extensive spinal cord (SC) lesions spanning three or more vertebral segments on Magnetic Ressonance Image (MRI). Even that LETM carries a considerable diagnostic challenge, has been regarded as a spectrum of Neuromyelitis optica (NMO). The seropositivity for NMO IgG, a specific biomarker of NMO, is variable in LETM patients around the world and reach 30-35% in brazilian series.
In 2004, a highly disease-specific autoantibody named NMO-IgG was discovered in patients with neuromyelitis optica (NMO) and NMO related diseases (i.e. relapsing optic neuritis and longitudinally extensive transverse myelitis). The target antigen of NMO-IgG was identified as aquaporin-4 (AQP4), the main water channel protein in the central nervous system (CNS).
Background: Neuromyelitis optica (NMO) is an aggressive devastating autoimmune disorder affecting predominantly optic nerves and the spinal cord. We are able to assess the serum antibodies against aquaporin 4 (anti-AQP4 Ab, also known as NMO-IgG), which are highly sensitive and specific for NMO.
INTRODUCTION: The description of a highly sensitive and specific biomarker for neuromyelitis optica (NMO-IgG/aquaporin-4 antibody) extended the clinical spectrum of NMO to limited forms such as optic neuritis (ON) and longitudinally extensive myelitis (LEM). OBJECTIVE: To asses the sensitivity and specificity of our assay, and to describe the clinical characteristics of the patients who were tested for NMO-IgG. METHODS: NMO-IgG was analysed by immunohistochemistry and confirmed by assay on HEK cells transfected with aquaporin-4.
We report a 25-year-old woman who developed optic neuritis and encephalomyelitis following primary Sjogren’s syndrome (SjS).
Neuromyelitis optica (NMO) is a relapsing inflammatory disorder of the central nervous system that closely resembles multiple sclerosis.